Tag: BioE3 Policy
The Structural Insolvency of Synthetic Platforms
Why Ginkgo’s $930 Million Revenue Gap Forced a Pivot to Vertical Product R&D
8 Min Read
Stop Renting Biology: The Mandatory Pivot to Proprietary Asset Ownership
Synthetic Biology Business Models: Transitioning From Platform Foundries to Asset Creation
8 Min Read
The Asset Sovereignty Mandate: Why ‘Horizontal’ Synbio Platforms Are Starving in 2026
Synthetic Biology Business Models: Replacing Horizontal Foundries with Asset Sovereignty
6 Min Read

